323
Views
4
CrossRef citations to date
0
Altmetric
Cochrane Corner

Cochrane corner: platinum-induced hearing loss after treatment for childhood cancer

, &
Pages 181-184 | Received 23 Jul 2018, Accepted 19 Oct 2018, Published online: 13 Dec 2018

References

  • Auletta, J. J., M. A. O'Riordan, and M. L. Nieder. 1999. “Infections in Children with Cancer: A Continued Need for the Comprehensive Physical Examination.” Journal of Pediatric Hematology/Oncology 21 (6): 501–508. doi:10.1097/00043426-199911000-00010
  • Bertolini, P., M. Lassalle, G. Mercier, M. A. Raquin, G. Izzi, N. Corradini, O. Hartmann., et al. 2004. “Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-up Reveals Continuous Worsening Of Hearing Loss.” Journal of Pediatric Hematology-Oncology 26 (10): 649–655. doi:10.1097/01.mph.0000141348.62532.73
  • Brock, P. R., R. Maibach, M. Childs, K. Rajput, D. Roebuck, M. J. Sullivan, V. Laithier., et al. 2018. “Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.” The New England Journal of Medicine 378 (25): 2376–2385. doi:10.1056/NEJMoa1801109
  • Dean, J. B., S. S. Hayashi, C. M. Albert, A. A. King, R. Karzon, and R. J. Hayashi. 2008. “Hearing Loss in Pediatric Oncology Patients Receiving Carboplatin-Containing Regimens.” Journal of Pediatric Hematology/Oncology 30 (2): 130–134. doi:10.1097/MPH.0b013e31815d1d83
  • Gallagher, K. L., and J. K. Jones. 1979. “Furosemide-Induced Ototoxicity.” Annals of Internal Medicine 91 (5): 744–745. doi:10.7326/0003-4819-91-5-744
  • Gietema, J. A., M. T. Meinardi, J. Messerschmidt, T. Gelevert, F. Alt, D. R. Uges, D. T. Sleijfer., et al. 2000. “Circulating Plasma Platinum More than 10 Years after Cisplatin Treatment for Testicular Cancer.” Lancet (London, England) 355 (9209): 1075–1076. doi:10.1016/S0140-6736(00)02044-4
  • Gregg, R. B., L. S. Wiorek, and J. C. Arvedson. 2004. “Pediatric Audiology: A Review.” Pediatrics in Review 25 (7): 224–233. doi:10.1542/pir.25-7-224
  • Karasawa, T., and P. S. Steyger. 2015. “An Integrated View of Cisplatin-Induced Nephrotoxicity and Ototoxicity.” Toxicology Letters 237 (3): 219–227. doi:10.1016/j.toxlet.2015.06.012
  • Knight, K. R., D. F. Kraemer, and E. A. Neuwelt. 2005. “Ototoxicity in Children Receiving Platinum Chemotherapy: underestimating a Commonly Occurring Toxicity That May Influence Academic and Social Development.” Journal of Clinical Oncology 23 (34): 8588–8596. doi:10.1200/JCO.2004.00.5355
  • McHaney, V. A., G. Thibadoux, F. A. Hayes, and A. A. Green. 1983. “Hearing Loss in Children Receiving Cisplatin Chemotherapy.” The Journal of Pediatrics 102 (2): 314–317. doi:10.1016/S0022-3476(83)80551-4
  • Reddel, R. R., R. F. Kefford, J. M. Grant, A. S. Coates, R. M. Fox, and M. H. Tattersall. 1982. “Ototoxicity in Patients Receiving Cisplatin: importance of Dose and Method of Drug Administration.” Cancer Treatment Reports 66 (1): 19–23.
  • Skinner, R. 2004. “Best Practice in Assessing Ototoxicity in Children with Cancer.” European Journal of Cancer (Oxford, England: 1990) 40 (16): 2352–2354. doi:10.1016/j.ejca.2004.08.002
  • Van As, J. W., H. van den Berg, and E. C. van Dalen. 2016a. “Platinum-Induced Hearing Loss after Treatment for Childhood Cancer.” Cochrane Database of Systematic Reviews 8: CD010181. doi:10.1002/14651858.CD010181.pub2.
  • Van As, J. W., H. van den Berg, and E. C. van Dalen. 2016b. “Medical Interventions for the Prevention of Platinum-Induced Hearing Loss in Children with Cancer.” The Cochrane Database of Systematic Reviews 9: CD009219. doi:10.1002/14651858.CD009219.pub4.
  • Van As, J. W., H. van den Berg, and E. C. van Dalen. 2018. “Different Infusion Durations for Preventing platinum-induced hearing loss in children with cancer.” The Cochrane Database of Systematic Reviews 7: CD010885. doi:10.1002/14651858.CD010885.pub4.
  • Van Dalen, E. C., H. J. van der Pal, W. E. Kok, H. N. Caron, and L. C. Kremer. 2006. “Clinical Heart Failure in a Cohort of Children Treated with Anthracyclines: A Long-Term Follow-up Study.” European Journal of Cancer 42 (18): 3191–3198. doi:10.1016/j.ejca.2006.08.005
  • Van der Pal, H. J., E. C. van Dalen, E. van Delden, I. W. van Dijk, W. E. Kok, R. B. Geskus, E. Sieswerda., et al. 2012. “High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors.” Journal of Clinical Oncology 30 (13): 1429–1437. doi:10.1200/JCO.2010.33.4730

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.